9:18 AM
 | 
Mar 09, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vanda's Hetlioz meets in Phase III for jet lag disorder

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) reported data from the double-blind, U.S. Phase III JET8 trial in 318 healthy volunteers undergoing a circadian challenge of an eight hour advance to their usual bedtime to induce jet lag disorder showing that 20 mg oral Hetlioz tasimelteon (VEC-162) met the primary endpoint of improving total sleep time in the...

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >